ESR1 and breast carcinoma: In contrast with the antiestrogen-mediated treatment of ER-positive adenocarcinomas and the trastuzumab-mediated treatment of HER-2-amplified cancers, no targeted therapy is available for TNBC, which is responsible for most breast cancer-associated deaths [3].